TROPION-Urothelial03: what clinicians are saying
datopotamab deruxtecan in advanced urothelial carcinoma after enfortumab vedotin plus pembrolizumab · NCT07129993 ↗ · Phase 2/Phase 3 · Daiichi Sankyo
A urologist frames TROPION-Urothelial03 as addressing platinum’s limited activity, while a speaker’s relayed assessment describes platinum as still active; the estimates use different measures and are not directly comparable. The urologist cites TROP2 expression as grounds for investigation, not demonstrated benefit. Trial-specific commentary is limited; FGFR3/HER2 testing and trials for fit patients provide treatment-choice context. These accounts cannot establish comparative benefit or trial-specific tolerability.
Created with AI · how we check it
- edition 1
- commentary checked Nov 20, 2026
- 25 verified statements
This edition $750, with MCP access for your AI agent. Get this report
4 findings, and what sits behind each
01. Platinum after EV/pembrolizumab: where clinicians split on its activity
2 of the report's 4 cited clinicians · 7 statements from 2 speakers in 5 sources · 5 passages
Limitations recorded: 3.
Draws on: The comparison, Population and setting, Design and conduct.
02. TROP2 after EV/pembrolizumab: what speakers say
3 of the report's 4 cited clinicians · 12 statements from 3 speakers in 5 sources · 8 passages
Limitations recorded: 3.
Draws on: Population and setting, The comparison, Design and conduct, Primary endpoint: Overall Response Rate - Part A (Phase 2), Primary endpoint: Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3), Primary endpoint: Overall Survival - Part B (Phase 3).
Beyond the trial population
03. Sequencing: what speakers say
1 of the report's 4 cited clinicians · 2 statements from 1 speaker in 2 sources · 2 passages
Limitations recorded: 3.
04. After EV/pembrolizumab: what speakers say
1 of the report's 4 cited clinicians · 4 statements from 1 speaker in 3 sources · 3 passages
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 4
2 of the report's 4 cited clinicians
Platinum after EV/pembrolizumab: where clinicians split on its activity
7 statements from 2 speakers in 5 sources
2 of the 2 named speakers in this finding take a side on this question; every named speaker in this finding is a confirmed clinician
- 7
- statements
- 5
- passages
- 5
- sources
- 2
- speakers
What the statements areViews 4Questions and uncertainty 1Clinical experience 0Comparisons 0Restated results and context 2Statement-to-passage links (a passage can back several statements)Supporting a statement 8Giving context 1Recorded with the findingLimitations: 3
4 posts and articles · 1 publication
Draws on: The comparison, Population and setting, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
2 of the 4 findings and 6 of the 25 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (6)
ADC, antibody–drug conjugate; BICR, blinded independent central review; HCP, healthcare professional; HER2, human epidermal growth factor receptor 2; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians.
The full TROPION-Urothelial03 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What randomized evidence do clinicians need from TROPION-Urothelial03 on response and survival with datopotamab deruxtecan plus platinum versus gemcitabine plus platinum in advanced urothelial carcinoma progressing after enfortumab vedotin plus pembrolizumab, given differing accounts of platinum activity?
From finding F1 (7 statements from 2 speakers in 5 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 12commentary sources screened
- 9sources cited by verified statements
- 4named in screened sources
- 4speakers cited in the report
- 4cited speakers with a verified identity
4 cited clinicians, speakers with a confirmed clinical role, of them 4 physicians. By role and specialty:
- 2 physician, Medical oncology
- 1 physician, specialty not confirmed
- 1 physician, Urology
Also in the sources: 3 organizational or shared accounts, not counted as people.
- 25verified statements, each linked to its source
- 12of them from speakers with a confirmed clinical role
- 4findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 25 | Paid |
| Who said each statement: the cited speakers | 4 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 4 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 9 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
10 discussed · 4 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Overall Response Rate - Part A (Phase 2) | 1 | 1 |
| Primary endpoint: Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3) | 1 | 1 |
| Primary endpoint: Overall Survival - Part B (Phase 3) | 1 | 1 |
| Secondary endpoint: Duration of Response - Part A (Phase 2)no commentary found | 0 | 0 |
| Secondary endpoint: Progression Free Survival as Assessed by Investigator - Part B (Phase 3)no commentary found | 0 | 0 |
| Secondary endpoint: Overall Response Rate - Part B (Phase 3)no commentary found | 0 | 0 |
| Population and setting | 7 | 5 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 8 | 5 |
| Safety and tolerabilityno commentary found | 0 | 0 |
| Design and conduct | 2 | 1 |
| Post-EV/pembrolizumab unmet need and sequencing uncertainty | 6 | 6 |
| TROP2 rationale and expectations for investigation | 3 | 3 |
| Routine-care alternatives and upfront biomarker work-up | 2 | 2 |
| Fit-patient trial preference and alternative ADC regimens | 2 | 2 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
25 verified statements from 9 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Posts · 18 statements · 72% | ||||
| X threads | 15 | 6 | 11 | |
| LinkedIn posts | 3 | 1 | 1 | |
| Primary sources · 7 statements · 28%cited for context, not screened | ||||
| Publications | 6 | 1 | — | |
| Registry | 1 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 4 / quarter
- Screened window
- Feb 28, 2026 → Nov 13, 2026
- Cited window
- Feb 28, 2026 → Nov 13, 2026
- Retrieved
- Nov 20, 2026
The trial
from ClinicalTrials.gov- Title
- A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)
- Registry
- NCT07129993
- Study IDs
- DS1062-328
- Sponsor
- Daiichi Sankyo
- Collaborators
- AstraZeneca
- Design
- Phase 2/Phase 3 · Interventional, randomized, sequential
- Status
- Recruiting
- Enrollment
- 630 estimated
- Registered
- 2025-08-19
- Start
- 2025-09-26 actual
- Primary completion
- 2029-06-01 estimated
- Primary endpoints
- Overall Response Rate - Part A (Phase 2)
- Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3)
- Overall Survival - Part B (Phase 3)
- Interventions
- 4 registered
More on: Urothelial carcinoma, datopotamab deruxtecan
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on platinum chemotherapy, biomarker-directed therapies, emerging antibody-drug conjugates and clinical trials after EV plus pembrolizumab.
- 13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 43 sources about other trials or topics are not included.
- The available discussion is concentrated in public posts and short summaries. Full talks and reviews are not represented, so the reasoning behind some estimates and preferences cannot be fully assessed.
Show all 11 known gaps +Fewer −
- Reposts and quoted posts do not establish additional independent HCP views or agreement.
- Platinum estimates differ in endpoint, wording and evidence source. They should not be combined into a single expected response or survival estimate for the trial's comparator.
- The review's lack of a signal favoring cisplatin over carboplatin is not evidence of equivalence.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The TROPION-Urothelial03 material used here describes methods and prospective expectations. Supporting observations from other Dato-DXd studies concern different regimens and, for TROPION-Lung04, a different cancer.
- Post dates are not presentation or session dates and do not establish changes in a clinician's opinion.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 20, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. TROPION-Urothelial03 (NCT07129993): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/tropion-urothelial03-nct07129993
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "TROPION-Urothelial03" (NCT07129993), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "tropion-urothelial03-nct07129993". If you cannot make requests, read https://www.erudio.com/reports/tropion-urothelial03-nct07129993.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT07129993", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT07129993 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/tropion-urothelial03-nct07129993.json
curl https://www.erudio.com/reports/tropion-urothelial03-nct07129993.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "tropion-urothelial03-nct07129993" })release a47fa664a78565558530a560d4fe9baada48d52d5c3418a9573127dc2193fdfb
Questions
How much does the TROPION-Urothelial03 report cost?
One edition costs $750 (Focused · 25 verified statements · 12 from 4 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the TROPION-Urothelial03 report cover?
25 statements from 9 sources (7 posts, 1 paper, 1 registry record), 12 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the TROPION-Urothelial03 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "tropion-urothelial03-nct07129993" }) previews it and create_order({ "report": "tropion-urothelial03-nct07129993", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the TROPION-Urothelial03 report?
Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.